SYNLOGIC INC (SYBX)
US87166L2097 - Common Stock
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform...
Synlogic Adopts Limited Duration Stockholders Rights Plan
Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process
Synlogic Adopts Limited Duration Stockholders Rights Plan
Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process...
Synlogic shares crater amid company shut down, failed drug study (NASDAQ:SYBX)
Synlogic (SYBX) stock was trading nearly 50% lower midday Friday, the day after the company announced it was pulling the plug on its lead drug program and shutting down operations.
Why Is CleanSpark (CLSK) Stock Up 27% Today?
CleanSpark stock is rising higher on Friday as investors in CLSK shares celebrate the company's positive Q1 earnings report.
Why Is BioXcel Therapeutics (BTAI) Stock Down 26% Today?
BioXcel Therapeutics stock is falling on Friday after the company announced plans for a proposed public offering of BTAI shares.
Why Is Synlogic (SYBX) Stock Down 55% Today?
Synlogic stock is falling hard on Friday with heavy trading of SYBX shares after the discontinuation of a clinical trial.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Synlogic to discontinue lead drug program, cease operations (NASDAQ:SYBX)
Synlogic (SYBX) said it has decided to cease operations after determining that a key clinical study for its drug SYNB1934 in the treatment of phenylketonuria wo
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe...
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in...
Synlogic Provides Corporate Update and Outlook for 2024
Synlogic Provides Corporate Update and Outlook for 2024
- Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age - -...
Synlogic bags contract to develop live probiotic products (NASDAQ:SYBX)
Synlogic, a biotech company, has secured a contract with the Air Force Research Lab to develop live probiotic products.
Synlogic Announces Contract with the Air Force Research Lab
- Selection of Synlogic reflects Company’s leadership in process development and manufacturing of therapeutics based on synthetic biology -
Synlogic Announces Contract with the Air Force Research Lab
- Selection of Synlogic reflects Company’s leadership in process development and manufacturing of therapeutics based on synthetic biology -...
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation - ...
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of...
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral,...